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A B S T R A C T
Background
Childhood obstructive sleep apnoea (OSA) is a disorder that is characterised by repeated episodes of partial or complete upper airway
obstruction (UAO) during sleep that result in disruption of normal ventilation and sleep patterns. Chronic cough in children is a
significant medical problem and in some situations warrants thorough investigation. There may be an association between chronic
cough and OSA as suggested in adult studies.
Objectives
To evaluate the efficacy of treatment of OSA leading to the resolution of cough in the management of children with chronic cough.
Search methods
We searched the Cochrane Register of Controlled Trials (CENTRAL, The Cochrane Library), MEDLINE and EMBASE. The latest
search was performed in September 2010.
Selection criteria
All randomised controlled trials comparing an intervention for OSA to a control group (placebo or usual treatment) in children with
chronic cough.
Data collection and analysis
We reviewed the search results against the pre-determined criteria for inclusion. Two review authors independently selected the studies.
No eligible trials were identified and thus no data were available for analysis.
Main results
We found no randomised controlled trials that examined the efficacy of treatment of OSA in the management of children with chronic
cough.
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Authors’ conclusions
There is currently no evidence that therapies directed for OSA are useful for the management of chronic cough in children. Until
further evidence is available, OSA should be managed on its own merits and the presence or absence of cough should not be used as a
decision trigger. Further research examining the effects of this intervention is needed.
P L A I N L A N G U A G E S U M M A R Y
Does treating obstructive sleep apnoea in children who also have chronic cough improve their cough?
Sleep apnoea (a condition where breathing stops for short spells during sleep) and chronic cough in children are significant medical
problems and cause a significant burden of distress to parents. Interventions for sleep apnoea are associated with risks of morbidity and
mortality, in addition to substantial costs. This review aimed to examine the effect of the treatment of sleep apnoea in children with
chronic cough, however no randomised controlled trials were found. Currently there is no evidence to support the use of interventions
for sleep apnoea in children with chronic cough and a randomised controlled trial is needed.
B A C K G R O U N D
Description of the condition
Obstructive sleep apnoea (OSA) has been reported as a cause of
chronic cough in adults. Data are scarce in children despite the fact
that OSA and chronic cough are relatively common. Also when
two symptoms are common, the chance occurrence of having both
symptoms is high. Thus the association between cough and OSA
symptoms may not be causal.
OSA belongs to the severe end of a spectrum of sleep-disordered
breathing (SDB). Within the OSA syndrome (OSAS), a spectrum
also exists and some mild OSAmay not require treatment (Littner
2007).
Childhood OSA is a disorder that is characterised by repeated
episodes of partial or complete upper airway obstruction (UAO)
during sleep that result in disruption of normal ventilation and
sleep patterns (American Thoracic Society 1996). An obstructive
apnoea is a respiratory event where there is absence of airflow with
continued respiratory effort, derived from the nasal pressure and
the thermistor signal during the polysomnogram. This is associ-
ated with an arousal, oxygen desaturation or autonomic activa-
tion (Chokroverty 2005). The most common cause for childhood
OSA is adenotonsillar hypertrophy, but the large tonsils and ade-
noids alone cannot account for the entire pathophysiologic pro-
cess. There is accumulating evidence to suggest that OSA is re-
lated to an interaction of structural and neuromuscular variables
within the upper airway. A recent study revealed that childhood
OSA was related to impaired response of the central nervous sys-
tem to mechanical stimulation of the respiratory system (Huang
2008).Thus, structural factors alone cannot be fully responsible
for this condition. The mechanism underlying this condition is
related to a combination of three processes: (1) decreased upper
airway patency (adenotonsillar hypertrophy, allergies associated
with chronic rhinitis or nasal obstruction), (2) reduced capacity to
maintain airway patency related to neuromuscular tone (obesity,
neuromuscular disorder), and (3) decreased drive to breathe (brain
stem injury) (Au 2009). OSAS may result in considerable mor-
bidity and perhaps mortality if left untreated. Complications of
untreated childhood OSA include possible cardiovascular conse-
quences, inflammatory associations, the metabolic syndrome and
growth failure.
Case series on chronic cough in adults have reported that one of
the possible aetiological factors is OSA (Birring 2007). A retro-
spective review on adults with chronic cough reported that OSA
was a common finding, even when another cause of cough was
identified and that interventions to optimise the SDB led to an im-
provement in the cough (Sundar 2010). The pathogenesis remains
unclear, although patients with OSA also have a high prevalence
of gastro-oesophageal reflux disease (Ing 2000). Other aetiological
factors associated with OSA may include laryngeal oedema, par-
ticularly of the arytenoid cartilages, and changes in cough thresh-
old secondary to changes to laryngeal sensitivity. In a cross-sec-
tional study, snoring in preschool children was found to be sig-
nificantly associated with both nocturnal cough and asthma (Lu
2003). However symptoms of OSA, particularly snoring in chil-
dren, are common, with a population prevalence of habitual snor-
ing as high as 12% (Ali 1993). The literature suggests a prevalence
of OSA from 0.1% to 13%, but most report a figure between
1% and 4% (Au 2009; Gislason 1995; Redline 1999). Hence the
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symptoms may co-exist by chance alone. Nevertheless other bi-
ologically plausible mechanisms may also account for the asso-
ciation between cough and OSA. These include recurrent small
volume aspiration in association with childhood OSA and prim-
ing of cough receptors leading to increased cough sensitivity from
mechanical vibration of the airways from snoring.
Description of the intervention
Types of intervention for OSA in children include adenoton-
sillectomy, non-invasive positive pressure ventilation (NIPPV),
leukotriene receptor antagonist, nasal corticosteroid therapy and/
orweight loss. Adenotonsillectomy is considered the cardinal treat-
ment of childhood OSA. Nasal corticosteroids have been exam-
ined as an alternative to adenotonsillectomy in otherwise healthy
children with OSA (Brouillette 2001; Demain 1995). Nasal cor-
ticosteroids work by exerting lympholytic action and effects on
inflammation and upper airway oedema (Kiely 2004). In an open-
labelled study, the leukotriene receptor antagonist, montelukast
was found to be clinically effective in reducing disease severity in
children with mild OSA (Goldbart 2005). A combination of in-
tranasal steroids and leukotrienemodifier was found to be useful in
childrenwith residualOSA after adenotonsillectomy (Kheirandish
2006).Nasal continuous positive airway pressure (CPAP) provides
positive pressure to the lumen of the airway and decreases airway
collapsibility. Weight loss is recommended as supplementary ther-
apy for obese children.
How the intervention might work
The pathophysiology onOSApossibly causing cough is unknown.
Possible reasons include increased risk of aspiration during sleep
when airway obstruction is present and/or stimulation of cough
receptors during the vibrations that occurs with airway collapse.
Interventions that remove or decrease airway obstruction during
sleep may thus improve cough.
Adenotonsillar hypertrophy is the most common cause of child-
hood OSA, hence adenotonsillectomy to remove the obstruction
that causesOSA. In childhoodOSA, nasal CPAPor bilevel positive
airway pressure (BiPAP) have become established themselves as the
second-line treatment or as first-line treatment in cases where ade-
notonsillectomy is contraindicated (Guilleminault 1986; Marcus
1995; Waters 1995). Nasal CPAP to the lumen of the airway de-
creases airway collapsibility.Demain 1995 demonstrated that nasal
corticosteroids over a 24-week treatment period reduced adenoidal
size and improved symptoms of nasal airway obstruction. Nasal
corticosteroids with or without leukotriene receptor antagonist are
an option for children with mild OSA related to nasal obstruction
caused by allergic rhinitis (Au 2009).
Any treatment, however, may demonstrate physiological or
placebo-related improvements. In cough-related studies, the pe-
riod effect (spontaneous resolution of cough) can be as high as
80% (Eccles 2002) and thus comparison to a placebo arm is very
important.
Why it is important to do this review
Cough is the most common symptom presenting to general prac-
titioners (Britt 2002; Cherry 2003). Worldwide, the desire to re-
duce the impact of the symptom of cough is reflected in the bil-
lions of dollars spent on over-the-counter cough and cold medica-
tions. Cochrane reviews on other interventions for chronic cough
are available (Chang 2007; Schroeder 2004).
General management of children with non-specific cough cur-
rently involves the ’watch, wait, and review’ approach (Chang
2006). For specific cough the intervention is for the presumed
aetiology. However some interventions including that for OSA
may be invasive (such as adenotonsillectomy) with an associated
small but significant risk of morbidity and mortality. Other in-
terventions for OSA such as NIPPV strategies have substantial
cost implications. Thus a systematic review of the efficacy of OSA
treatments for chronic cough would be useful in assessing the risk
versus benefit details of the therapy, in order to help guide clinical
practice.
O B J E C T I V E S
To evaluate the efficacy of treatment of OSA leading to the resolu-
tion of cough in the management of children with chronic cough.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials comparing any treatment forOSA
to a control group (placebo or usual treatment) in children with
chronic cough.
Types of participants
Children with chronic (greater than four weeks) cough in associ-
ation with OSA symptoms (snoring, increased respiratory effort,
choking during sleep, restlessness, frequent awakening, excessive
sleepiness, tiredness, fatigue, nocturnal enuresis, poor attention
span, hyperactivity, poor school performance, aggressiveness, fail-
ure to thrive and/or other behavioural disturbances).
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Exclusion criteria: acute (less than two weeks) or sub-acute (two
to four weeks) cough, cough related to mycoplasma, pertussis and
chlamydia, presence of underlying cardio-respiratory condition,
current or recurrent wheeze (more than two episodes), presence
of other obvious causes of chronic cough (e.g. bronchiectasis) or
other respiratory symptoms (e.g. productive cough, haemoptysis,
dyspnoea).
Types of interventions
All randomised controlled trials comparing an intervention for
OSA to a control group (placebo or usual treatment) with cough
determined as an outcome. These interventions will be grouped
into pharmaceutical therapy such as nasal corticosteroids and
leukotriene receptor antagonists, NIPPV and surgery (adenoton-
sillectomy).
Types of outcome measures
Primary outcomes
a) proportions of participants who were not cured or not substan-
tially improved at follow-up (clinical failure).
Secondary outcomes
b) proportions of participants who were not cured at follow-up,
c) proportions of participantswhowere not substantially improved
at follow-up,
d) mean difference in cough-specific indices (quality of life, cough
diary, cough frequency, cough scores),
e) proportions experiencing adverse effects of the intervention,
f ) proportions experiencing complications e.g. requirement for
medication change, etc.
The proportions of participants who failed to improve on treat-
ment and the mean clinical improvement were determined using
the following hierarchy of assessment measures (i.e. where two or
more assessment measures are reported in the same study, the out-
come measure that was listed first in the hierarchy was used):
i) Objective measurements of cough indices (cough frequency,
cough receptor sensitivity).
ii) Symptomatic (Quality of life, Likert scale, visual analogue scale,
level of interference of cough, cough diary) - assessed by the patient
(adult or child).
iii) Symptomatic (Quality of life, Likert scale, visual analogue scale,
level of interference of cough, cough diary) - assessed by the par-
ents/carers.
iv) Symptomatic (Likert scale, visual analogue scale, level of inter-
ference of cough, cough diary) - assessed by clinicians.
Search methods for identification of studies
Electronic searches
We used the following topic search strategy to identify the relevant
randomised controlled trials listed on the electronic databases:
(“cough” OR “bronchitis”, all as (textword) or (MeSH )) AND
(“sleep” AND (“apnea” OR ’apnoea“ OR ”hypopnea“ OR ”hy-
popnoea“ OR ”obstructive“ OR ”disorder“ OR ”disturbance“ OR
”disordered breathing“ OR ”snore“ OR ”snoring“ OR ”breath-
ing“ all as (textword) or (MeSH )) AND (”child“ OR ”children“
OR ”pediatrics“ OR ”paediatrics“ all as (textword) or (MeSH )).
The full strategies are listed in Appendix 1.
We sought trials from the following sources:
1. The current Cochrane Central Register of Controlled Trials
(CENTRAL,The Cochrane Library), which includes theCochrane
Airways Group Specialised Trials Register.
2. MEDLINE (1966 to current).
3. OLDMEDLINE (1950 to 1965).
4. EMBASE (1980 to current).
Searching other resources
5. The list of references in relevant publications.
6. Written communication with the authors of trials included in
the review.
The search was performed in September 2010.
Data collection and analysis
Selection of studies
Retrieval of studies: From the title, abstract, or descriptors, two
authors (LT and AC) independently reviewed literature searches to
identify potentially relevant trials for full review. Searches of bib-
liographies and texts were conducted to identify additional stud-
ies. From the full text using specific criteria, the same two authors
independently assessed trials for inclusion. Disagreement was re-
solved by consensus.
Data extraction and management
We planned to review eligible studies and record the following
information: study setting, year of study, source of funding, pa-
tient recruitment details (including number of eligible subjects),
inclusion and exclusion criteria, other symptoms, randomisation
and allocation concealment method, numbers of participants ran-
domised, blinding (masking) of participants, care providers and
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outcome assessors, dose and type of intervention, duration of ther-
apy, co-interventions, numbers of patients not followed up, rea-
sons for withdrawals from study protocol (clinical, side-effects, re-
fusal and other), details on side-effects of therapy, and whether in-
tention-to-treat analyses were possible. We also planned to extract
data on the previously described outcomes. Further information
would have been requested from the trial authors where required.
Assessment of risk of bias in included studies
We planned to assess the risk of bias using the ’risk of bias tool’ in
RevMan 5 according to recommendations in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2008; Review
Manager). Two authors (LT and AC) would have independently
assessed the quality of the included studies using the following
headings: 1) sequence generation; 2) allocation concealment; 3)
blinding; 4) incomplete outcome data; 5) selective outcome re-
porting; and 6) other bias. Each domain would have been assessed
as either high, low or unclear risk of bias. Inter-reviewer reliability
for the identification of high quality studies for each component
would have been measured by the Kappa statistic.
Dealing with missing data
We planned to request further information from the trial authors
where required.
Assessment of heterogeneity
We planned to describe any heterogeneity between the study re-
sults and test this to see if it reached statistical significance using
the Chi2 test. We consider heterogeneity to be significant when
the P value is less than 0.10 (Higgins 2008).
Assessment of reporting biases
If combining the data and meta-analysis had been possible, we
planned to assess publicationbias using a funnel plotwhen relevant
(greater than five trials). We also planned to identify and report
on any selective reporting in the included trials.
Data synthesis
For the dichotomous outcome variables of each individual study,
relative and absolute risk reductions would have been calculated
using a modified intention-to-treat analysis. This analysis assumes
that children not available for outcome assessment have not im-
proved (and probably represents a conservative estimate of effect).
An initial qualitative comparison of all the individually analysed
studies would have examined whether pooling of results (meta-
analysis) was reasonable. This would take into account differences
in study populations, inclusion/exclusion criteria, interventions,
outcome assessment, and estimated effect size.
The results from studies that met the inclusion criteria and re-
ported any of the outcomes of interest would have been included
in the subsequent meta-analyses. The summary weighted risk ratio
and 95% confidence interval (fixed-effect model) were to be cal-
culated using Revman 5. Numbers needed to treat (NNT) were to
be calculated from the pooled odds ratio and its 95% confidence
interval applied to a specified baseline risk using an online calcu-
lator (Cates 2003). The average cough indices were to be assumed
to be normally distributed continuous variables so the mean dif-
ference in outcomes can be estimated (weighted mean difference).
If studies reported outcomes using different measurement scales,
the standardised mean difference was to be estimated. Any hetero-
geneity between the study results was to be described and tested to
see if it reached statistical significance using a Chi2 test. For cross-
over trials, only those not involving surgery were to be included
if the washout period was deemed adequate (at least eight weeks
for medication trials and four weeks for CPAP). Generic inverse
variance (GIV) of paired data were to be used for cross-overs and
could have been combined with parallel studies. The 95% con-
fidence interval estimated using a random-effects model was to
be included as part of a sensitivity analysis whenever there were
concerns about statistical heterogeneity.
Subgroup analysis and investigation of heterogeneity
We planned an a priori sub-group analysis for:
1. children with a syndrome (e.g. Down’s syndrome) versus
non-syndromic;
2. combined versus mono interventions.
Sensitivity analysis
We planned sensitivity analyses to assess the impact of potentially
important factors on the overall outcomes:
1. variation in the inclusion criteria;
2. differences in intervention types for the active arm and
comparison groups;
3. differences in outcome measures;
4. analysis using random-effects model;
5. analysis by ”treatment received“; and
6. analysis by ”intention-to-treat“.
R E S U L T S
Description of studies
See: Characteristics of excluded studies.
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Results of the search
The Airways Group search identified 138 potentially relevant ti-
tles. After assessing the abstracts, we retrieved eight studies (in-
cluding from references of reviews) for possible inclusion into re-
view but none fulfilled the study eligibility criteria.
Excluded studies
Therewere few controlled studies onOSA in children.Those avail-
able did not report on any cough severity measures, see Excluded
studies table. The main reason for excluding the studies related
to absence of any data on cough. One study evaluated cough in
asthmatic children who had nasal obstruction and mouth breath-
ing and not OSA (Henriksen 1984). Another described use of an-
tibiotics in children with chronic rhino-sinusitis, some of whom
had snoring but OSA was not described (El-Hennawi 2006). The
authors of two studies (El-Hennawi 2006; Li 2009) confirmed
they had no data relating to cough and snoring interventions.
Risk of bias in included studies
There were no included studies and hence risk of bias is not ap-
plicable.
Effects of interventions
There were no eligible studies.
D I S C U S S I O N
We identified no randomised controlled trials of OSA treatments
leading to the resolution of cough in children with chronic cough.
One study did evaluate the effect of an intranasal corticosteroid
(budesonide) in asthmatic children with a history of nasal obstruc-
tion andmouth breathing (Henriksen 1984). The study examined
its effect on asthma scores (which included cough) but did not
include children with OSA.
There is a lack of relevant data on children with cough associated
with OSA despite the commonality of snoring and cough in chil-
dren. The few RCTs on OSA did not examine cough, likely re-
flecting the infrequency of cough in children with OSA. However
cough has been reported in children in non-randomised controlled
trials; one case report described a three year-old boy who had
chronic nocturnal cough secondary to OSA (Teng 1997). Nasal
CPAP alleviated the persistent nocturnal coughing in this child
(Teng 1997). In a cross-sectional study, snoring in preschool chil-
dren was found to be significantly associated with both nocturnal
cough and asthma (Lu 2003). Because snoring, asthma and noc-
turnal cough may have a common aetiology, Lu 2003 concluded
that it is possible that effective treatment of one symptom may
lead to reductions in the presence or severity of the other symp-
toms. In adults with asthma, treatment of snoring and otherwise
mild OSA with nasal CPAP can lead to improvements in asthma
(Chan 1988).
In children, snoring is also said to be associatedwith chronic rhino-
sinusitis (El-Hennawi 2006). However as there are no cough re-
ceptors proximal to the larynx, it is likely but remains unknown
that reports of this association may reflect presence of protracted
bacterial bronchitis in children. Improvement of cough associated
with use of antibiotics for chronic rhino-sinusitis may reflect suc-
cessful treatment for cough associated with protracted bacterial
bronchitis (Marchant 2006) and hence the improvement. Snor-
ing was associated with chronic bronchitis in a prospective cohort
study on adults (Baik 2008). The causal relationship between snor-
ing and chronic bronchitis remains unclear, and the mechanisms
underlying the association are largely unknown. Given the associ-
ation of the severity of lower airway inflammation with upper air-
way inflammation and with systemic inflammation (Hurst 2006),
snoring may be linked to lower airway inflammation. In addition,
airway pressure gradients, which are triggered by intermittent air-
way obstruction occurring in snoring, may be transmitted to the
respiratory system, causing mechanical stress and resulting in in-
flammation (Salerno 2004).
Agreements and disagreements with other
studies or reviews
Case series on chronic cough in adults have reported that one of
the possible aetiological factors is OSA (Birring 2007). There were
only four adult patients in this study, all of whom had a rapid im-
provement of their coughwithCPAP therapy. A retrospective eval-
uation of management of adults with chronic cough reported that
OSA was a common finding, even when another cause of cough
was identified and that CPAP therapy lead to an improvement
in the cough (Sundar 2010). Corbo 1989 found that respiratory
symptoms in school aged children such as rhinitis and cough or
sputum production, previous tonsillectomy, and passive parental
smoking were associated with an increased prevalence of snoring.
Bloom 1988 reported the same association (snoring and cough or
sputum production) in adults. In univariate analysis Zhang 2009
also found increased allergic and other respiratory symptoms as
well as smoking and nitric nitrogen dioxide exposure (in winter)
in children with snoring.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no evidence to support or refute the efficacy of
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treatment of OSA for the management of cough in children with
chronic cough. Children with OSA should be managed according
to the severity of the OSA and not on the basis of cough until
further evidence is available. Mild OSA is not always treated (
Littner 2007). Interventions for mild OSA such as nasal CPAP or
surgery are only indicated for failed treatment in highly selected
cases (Littner 2007). The associated small but significant risk of
morbidity and mortality of some interventions for OSA (such
as adenotonsillectomy) must be considered if OSA therapies are
used for the outcome of cough. Other interventions for OSA such
as NIPPV have substantial cost implications and should also be
considered.
Implications for research
OSAwill always need to be treated on its own merits. However, in
mild OSA where cough is present, randomised controlled studies
to determine the effectiveness of OSA treatments in such settings
leading to the resolution of cough in children with chronic cough
are needed. Given the difference in aetiologies for both chronic
cough and OSA between adults and children, child-specific trials
are required. Trials should be parallel and preferably multi-centre
studies. In these trials, outcome measures should include cough
resolution rates in addition to clinical outcomes. Outcome mea-
sures for the clinical trials on cough should be clearly defined using
validated subjective data (including quality of life and cough di-
aries) and supported by objective data (such as cough frequency).
Analysis of costs and possible risks and/or adverse effects of in-
terventions for OSA such as adenotonsillectomy, NIPPV and/or
pharmaceutical therapy would also provide additional useful in-
formation.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Brouillette 2001 Randomised, triple-blind, placebo-controlled, parallel-group trial examining the effect of an intranasal
corticosteroid (fluticasone propionate) in 25 children with OSA. No cough outcomes measured
Don 2005 Randomised, double-blind trial evaluating the efficacy of a broad spectrum antibiotic (azithromycin) in
the management of adenotonsillar hypertrophy and OSA in 22 children. No cough outcomes measured
El-Hennawi 2006 Randomised controlled study in 60 children with persistent nasal discharge and nasal obstruction (and
other related symptoms e.g. chronic cough, snoring). The study did not assess children with OSA
El-Hennawi 2010 Non-randomised study in 180 children <2 years of age with subacute rhino-sinusitis (and other related
symptoms including chronic cough and snoring). The study was non-randomised and did not assess
children with OSA
Henriksen 1984 Randomised, double-blind, parallel study examining the effect of an intranasal corticosteroid (budesonide)
on nasal symptoms, mode of respiration (nasal versus mouth breathing) and asthma in 37 asthmatic
children who were mouth breathers because of chronic nasal obstruction. Cough was measured but the
study did not assess children with OSA
Kheirandish-Gozal 2008 Randomised, double-blind, crossover trial examining the use of an intranasal corticosteroid (budesonide)
in 62 children with mild OSA syndrome. No cough outcomes mentioned or measured
Li 2009 Randomised, double-blind, placebo-controlled study in 44 children with stable asthma and persistent
allergic rhinitis. No cough outcomes measured
Lojander 1996 Randomised study in 76 adults with OSA syndrome assessing the effectiveness and safety of nasal CPAP
and that of surgery in comparison to conservative management. No cough outcomes measured
McLean 2005 Randomised, placebo-controlled, single blind, crossover study in 10 adults with nasal obstruction and
OSA. No cough outcomes measured
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Database search strategies
CENTRAL search
#1 MeSH descriptor Cough explode all trees
#2 MeSH descriptor Bronchitis explode all trees
#3 cough* or bronchit*
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor Sleep Apnea Syndromes explode all trees
#6 (sleep near/3 (apnea* or apnoea*))




#11 MeSH descriptor Snoring, this term only
#12 (Breath* near/3 disorder*)
#13 (breath* near/3 obstruct*)
#14 (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 MeSH descriptor Pediatrics explode all trees
#16 MeSH descriptor Child explode all trees
#17 MeSH descriptor Infant explode all trees
#18 MeSH descriptor Adolescent explode all trees
#19 child* or paediat* or pediat* or adolesc* or infan* or toddler* or bab* or young* or preschool* or ”pre school*“ or pre-school* or
newborn* or ”new born*“ or new-born* or neo-nat* or neonat*
#20 (#15 OR #16 OR #17 OR #18 OR #19)
#21 (#4 AND #14 AND #20)
MEDLINE/OLD MEDLINE search
(Combined with RCT filter)
1 exp Cough/
2 exp BRONCHITIS/
3 (cough$ or bronchit$).mp.
4 or/1-3
5 exp Sleep Apnea Syndromes/
6 (sleep$ adj3 (apnea$ or apnoea$)).mp.





12 ((disorder* adj3 breath*) or (breath* adj3 disorder*)).mp.
13 ((obstruct* adj3 breath*) or (breath* adj3 obstruct*)).mp.
14 or/5-13
15 adolescent/ or exp child/ or exp infant/
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16 exp pediatrics/
17 (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$
or newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.
18 or/15-17
19 4 and 14 and 18
EMBASE search
(Combined with RCT filter)
1 exp COUGHING/
2 exp BRONCHITIS/
3 (cough$ or bronchit$).mp.
4 or/1-3
5 exp sleep apnea syndrome/
6 exp sleep disordered breathing/
7 (sleep$ adj3 (apnea$ or apnoea$)).mp.





13 ((disorder* adj3 breath*) or (breath* adj3 disorder*)).mp.
14 ((obstruct* adj3 breath*) or (breath* adj3 obstruct*)).mp.
15 or/5-14
16 exp adolescent/ or exp child/ or exp infant/ or exp newborn/
17 (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$
or newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.
18 exp pediatrics/
19 or/16-18
20 4 and 19 and 15
H I S T O R Y
Protocol first published: Issue 1, 2010
Review first published: Issue 4, 2011
C O N T R I B U T I O N S O F A U T H O R S
LT and AC wrote the protocol and review and independently reviewed potential abstracts and papers. All reviewed the submitted
review.
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